Lung cancer drug cocktail trial ends early – what we know
NCT ID NCT04619433
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 3 trial tested a combination of three drugs—camrelizumab (an immunotherapy), famitinib (a targeted therapy), and standard chemotherapy—in 48 people with advanced non-squamous non-small-cell lung cancer that did not have certain genetic changes. The study aimed to see if the combo worked better than chemo alone, but it was terminated early, so we have limited information on its effectiveness or safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Camrelizumab (an immunotherapy drug), Famitinib (a targeted therapy), and chemotherapy (pemetrexed and carboplatin)
What this could lead to
If successful, this combination could offer a new treatment option for people with a common type of lung cancer that lacks certain genetic mutations.
What could go wrong
The trial was terminated early with only 48 participants, so results are limited. It is unclear if the combination is safe or effective, and side effects from multiple drugs can be significant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SQUAMOUS NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Cancer Hosipital
Beijing, Beijing Municipality, 100089, China
-
Henan Cancer Hospital
Zhengzhou, Henan, 450003, China
-
Hubei Cancer Hospita
Wuhan, Hubei, 430079, China
-
Shanghai Lung Hospital
Shanghai, Shanghai Municipality, 200433, China
-
Shengjing Hospita of China Medical University
Shenyang, Liaoning, 110022, China
-
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, 300060, China
-
West China Hospital，Sichuan University
Chengdu, Sichuan, 610000, China